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ABSTRACT
Long non-coding RNA (lncRNA), highly up-regulated
in liver cancer (HULC) plays an important role in
tumorigenesis. Depletion of HULC resulted in a sig-
nificant deregulation of several genes involved in
liver cancer. Although up-regulation of HULC ex-
pression in hepatocellular carcinoma has been
reported, the molecular mechanisms remain
unknown. In this study, we used in vivo and
in vitro approaches to characterize cancer-
dependent alterations in the chromatin organization
and find a CREB binding site (encompassing from
 67 to  53nt) in the core promoter. Besides, we
also provided evidence that PKA pathway may
involved in up-regulation of HULC. Furthermore,
we demonstrated HULC may act as an endogen-
ous ‘sponge’, which down-regulates a series of
microRNAs (miRNAs) activities, including miR-372.
Inhibition of miR-372 leads to reducing translational
repression of its target gene, PRKACB, which in turn
induces phosphorylation of CREB. Over-expression
of miR-372 decreases the association of CREB with
the proximal promoter, followed by the dissociation
of P300, resulting in a change of the histone ‘code’,
such as in deacetylation and methylation. The study
elucidates that fine tuning of HULC expression is
part of an auto-regulatory loop in which it’s inhibi-
tory to expression and activity of miR-372 allows
lncRNA up-regulated expression in liver cancer.
INTRODUCTION
Eukaryotic genomes are not the simple, well-order sub-
strates of gene transcription that was once believed. We
now know them to transcribe a broad spectrum of RNA
molecules, ranging from long protein-coding mRNAs to
short non-coding transcripts, which frequently overlap or
are interleaved on either strand. The large proportion of a
eukaryotic genome that is transcribed thus produces a
huge array of RNA molecules diﬀering in size, abundance
and protein-coding capability (1).
In stark contrast to this diversity of RNA species, only a
small number of non-protein-coding transcripts currently
have experimentally-derived functions. Moreover, only
rarely have disease-associated mutations been identiﬁed
outside of protein-coding genes. Might, therefore, this
colorful pageant of genomic transcription be a mirage?
Might much of a genome’s repertoire of non-protein-
coding transcripts be inconsequential transcriptional
‘noise’? Wang et al. (2) reported that non-protein-coding
transcripts identiﬁed in mouse cDNA collections are
poorly conserved and therefore argued that they are
likely to be non-function. By contrast, many members of
known functional classes of non-coding RNAs (ncRNAs),
including microRNAs (miRNAs) are well-conserved
across a diverse range of species (3–5).
NcRNAs are grouped into three subclasses according to
their number of nucleotides (6,7). The growing class of
miRNAs (19–25nt) has been related to cell diﬀerentiation
and cancer in recent publications (8–11). Small ncRNAs
with a length of 100–200nt are commonly found as
*To whom correspondence should be addressed. Tel: +86 21 64370045; Fax: +86 21 64311744; Email: fan.qishi@yahoo.com
Correspondence may also be addressed to Fenyong Sun. Tel: +86 20 85223266; Fax: +86 20 85221983; Email: sunfenyong@126.com
The authors wish it to be known that, in their opinion, the ﬁrst two authors should be regarded as joint First Authors.
5366–5383 Nucleic Acids Research, 2010, Vol. 38, No. 16 Published online 27 April 2010
doi:10.1093/nar/gkq285
 The Author(s) 2010. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.translational repressors, and long ncRNAs (>200nt) are
reported involved in gene silencing (7). According to their
structural features, these three subclasses of heterogeneous
transcriptional units can be further subcategorized.
Hepatocellular carcinoma (HCC) is one of the deadliest
cancers, causing about half a million deaths each year
(12). Using a HCC-speciﬁc cDNA microarray platform,
Panzitt et al. (13) identiﬁed a novel mRNA-like long
ncRNA, highly up-regulated in liver cancer (HULC) as
one of the most up-regulated genes in HCC.
Up-regulation of HULC in colorectal carcinomas that me-
tastasize to the livers was independently described by
Matouk et al., in a later study, indicating that HULC is
not restricted to HCC, however, to some extent, depend-
ent on the liver micro-environment (14). However, the
mechanism involved in up-regulating expression of
HULC in HCC remains unknown.
Depletion of HULC in Hep3B cell line resulted in a
signiﬁcant deregulation of several genes, some of which
have already been reported in the context of liver cancer
(13). This indicates that there may not only be one single
HULC target gene, but rather suggests a more general
regulatory role for HULC. Disappointedly, preliminary
studies revealed no signiﬁcant homologies between
HULC and its putative target sequences, thus indicating
that the eﬀect of HULC on its targets may not base on
direct RNA–RNA interactions. Whether the mechanism
by which HULC aﬀects target gene expression constitutes
a common regulatory principle remains to be resolved.
The aim of the present study was to deﬁne the mechan-
ism responsible for the up-regulation of HULC in HCC
and thereby provide a basic model to aid future studies of
Hulc promoter regulation and the lncRNA function. We
ﬁnd that one cAMP response element binding protein
(CREB) binding site within the Hulc proximal promoter
region can speciﬁcally bind phospho-CREB transcription
factors through the PKA pathway and that mutation or
deletion of this site diminishes Hulc promoter activity in
liver cancer cells. Moreover, phospho-CREB is able to
‘open’ and maintain the local chromatin structure across
the Hulc promoter. We also demonstrated that HULC
RNA has the ability of inhibiting a series of miRNAs
activities, including miR-372. Inhibition of miR-372
leads to reducing translational repression of its target
gene, Prkacb, which can induce phosphorylation of
CREB (15). The regulatory circuitry described in this
study provides another example of how gene
reprogramming during tumorigenesis relies on ﬁne modu-
lation of gene expression. It is also interesting to note that
ﬁne tuning of lncRNA, HULC expression is part of an
autoregulatory loop in which it’s inhibitory to expression
and activity of miR-372 allows the establishment of the
lncRNA up-regulated expression in liver cancer.
MATERIALS AND METHODS
Patients and materials
Tumorous liver tissues and corresponding adjacent
non-tumoral liver tissue were collected from 14 patients
who underwent curative surgery for HCC at Ruijin
Hospital, Shanghai, China. Informed consent was
obtained from each patient recruited, and the study
protocol was approved by the Clinical Research Ethics
Committee of the Shanghai Jiaotong University school
of medicine. QSG-7701, Chang liver, HL-7702, Huh-1,
Huh-4, Hep3B, HepG2, Huh-7, SNU-449, SNU-475
cells were maintained in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) with 10% fetal bovine serum (FBS),
100U/ml penicillin and 100mg/ml streptomycin.
Antibodies were purchased from the following companies:
P300 (SC-584), Brg1 (SC-10768), Prkacb (SC-904), CREB
(SC-186), p-CREB (SC-7978), CBP (SC-7300) and RNA
polymerase II (SC-9001) from Santa Cruz Biotechnology
(Santa Cruz, CA, USA); tetra-acetyl-H4 (06-866) and
diacetyl-H3 (07-593) from Upstate (Charlottesville, VA,
USA); dimethyl-H3-K9 (ab1220) from Abcam
(Cambridge, MA, USA) and trimethyl-H3-K4 (9751)
from Cell Signaling Technology (Boston, MA, USA).
PKA inhibitor H89, and inhibitor of transcription,
a-amanitin were purchased from Sigma (St. Louis, MO,
USA).
Cell culture
To examine the eﬀects of H89 on HULC expression, cells
were incubated for 1day with indicated amount of H89.
Cells were transfected with 50nM miR-372 mimics,
siRNA against CREB, HULC, or Prkacb (GenePharma
Co. Ltd, Shanghai China) using Lipofectamine 2000
(Invitrogen Corp., Carlsbad, CA, USA) according to the
manufacturer’s instructions for indicated period of time
after replacement of transfection culture medium in the
DMEM with 5% FBS. Incubation with 50mg/ml
a-amanitin was performed for 1day.
50-RLM-RACE
The GeneRacer system (Invitrogen), based on RNA
ligase-mediated and oligo-capping rapid ampliﬁcation of
cDNA, was carried out according to the manufacturer’s
instructions. The kit ensures the ampliﬁcation of only
full-length transcripts by eliminating truncated messages
from the ampliﬁcation process. HULC-speciﬁc primers
located in the ﬁrst exon were used for ampliﬁcation by
PCR using the LaTaq GC-Rich PCR system (Takara,
Inc., Dalian, China).
Chromatin accessibility analysis of chromatin structure
Accessibility of DNA to digestion with DNase I and re-
striction enzymes (All from Takara, except Bra I from
New England Biolabs, Beverly, MA, USA) analyzed
using chromatin accessibility by real-time PCR
(CHART-PCR) as described previously (16,17). Brieﬂy,
nuclear pellets were re-suspended in 3ml of buﬀer A
(10mM Tris–HCl, pH 7.4, 10mM NaCl, 3mM MgCl2,
0.3M sucrose). Aliquots of nuclei were digested with
increasing concentrations of DNase I (0, 1, 3, 7U) in a
100ml ﬁnal volume with 1mM CaCl2 for 5min at room
temperature. The reaction was stopped by adding 100mlo f
stop buﬀer (50mM Tris–HCl, pH 7.5, 150mM NaCl,
50mM EDTA, 0.3% SDS) and incubated with 10U
RNaseA (Takara) at 37 C for 2h. The samples were
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(25 : 24 : 1) and once with chloroform. Nucleic acids
were precipitated with 0.7 volumes of isopropanol,
washed with 70% ethanol and resuspended in TE buﬀer.
For the restriction enzyme accessibility assays, nuclei were
isolated as described above and digested with 25–150U of
restriction enzyme in 100ml of the corresponding reaction
buﬀer for 30min at 37 C Reactions were terminated and
DNA was extracted as described earlier. After puriﬁca-
tion, 0.1mg DNA from nuclease-digested or non-digested
control cells was used in real-time PCR with the primer
sets listed in Supplementary Data. Percent protection was
calculated as the amount of DNA recovered from the di-
gested  cells relative to the control cells.
ChIP and Re-ChIP
Chromatin immunoprecipitation (ChIP) assays were per-
formed according to the manufacturer’s instructions
(Active Motif, Carlsbad, CA, USA). Brieﬂy, 2 10
6 cells
were ﬁxed with 1% formaldehyde, washed with cold
phosphate-buﬀered saline, and lysed in buﬀer. Nuclei
were sonicated to shear DNA, and the lysates were
pelleted and precleared. The protein–DNA complexes
were incubated with 4mg antibodies overnight and then
incubated with protein A beads followed by elution in
1% SDS/0.1M NaHCO3 and cross-links were reversed
at 65 C. At last, DNA was subjected to quantitative
PCR analysis after recovered. In the Re-ChIP experi-
ments, complexes were eluted by incubation for 30min
at 37 C in 25ml 10mM DTT. After centrifugation, the
supernatant was diluted 20 times with Re-ChIP buﬀer
(1% Triton X-100, 2mM EDTA, 150mM NaCl, 20mM
Tris–HCl, [pH 8.1]) and subjected again to the ChIP pro-
cedure. Real-time PCR reactions were performed in trip-
licate with 1ml of precipitated DNA. DNA recovered from
samples containing an antibody was compared with no
antibody negative controls performed on aliquots from
the same chromatin preparation. Data are presented as
the amount of DNA recovered relative to the appropriate
negative control antibody provided by the manufacturer.
In this way, diﬀerences between chromatin preparations
are normalized. The results were expressed as the
means±SDs of three independent experiments. The
PCR primers are available in Supplementary Data.
Reverse transcription PCR
Total RNA was extracted by Trizol reagent (Invitrogen).
Reaction mixture (20ml) containing 1mg of total RNA was
reverse transcribed to cDNA using PrimeScript
RT-polymerase (Takara). Quantitative PCR was per-
formed on the cDNA using primers speciﬁc for HULC,
CREB, Prkacb. Speciﬁcally, stem-loop reverse transcript-
ase polymerase chain reaction (RT-PCR) for mature
miR-372 was performed as described previously (18).
RNA input was normalized to the level of b-actin, both
for genes and miRNA analysis (19). All reaction were
carried out using SYBR Green Mix (Takara), and the
PCR conditions for quantitative RT-PCR were as
follows: activation of enzyme at 94 C or 5min, 40 cycles
of denaturation at 94 C for 30s, annealing at 55 C for
30s, and extension at 72 C for 20s. qRT-PCR was
carried out using a Mx3000P real-time PCR System
(Stratagene, La Jolla, CA, USA). The ﬂuorescence of
each sample was determined after every cycle. The ﬂuor-
escence of samples was continuously traced during this
period. Relative expression levels were calculated as
ratios normalized against those of b-actin. The data
from qRT-PCR were analyzed by the Ct method, and
the Ct value was determined by subtracting the b-actin
Ct value from the target gene Ct value. The Ct of the
stimulated cells (Cts) was subtracted from the Ct of the
untreated cells (Ctu) (Ct=Cts Ctu), and the ex-
pression level for a target gene in the stimulated cells
compared with the level in the untreated cells was
calculated as follows: x-fold of unstimulated con-
trol=2 C
t. All results are expressed as the
means±SD of three independent experiments. Primers
can be found in the Supplementary Data.
Construction of reporter and expression plasmids and
mutagenesis
PCR was performed using sets of oligonucleotide primers
speciﬁc for the Hulc promoter, of which the forward
primer was Mlu I-site-linked and the reverse primer Xho
I-site-linked. Hep3B or HL-7702 genomic DNA was used
as the template. These PCR products were digested with
Mlu I and Xho I, and cloned into the Mlu I/Xho I sites of
the pGL3-Basic vector (Promega, Madison, WI, USA),
yielding the promoter reporter plasmid. HULC, Prkacb
30-untranslated regions (UTR), and ﬂank sequences
around pre-miRNA, which containing miRNA putative
target sites were ampliﬁed from Hep3B or HL-7702
genomic DNA, and then were cloned into the Xho I/
Not I sites of psiCHECK vector (promega). For
over-expression studies, the complete cDNA sequence of
HULC was obtained from Hep3B cells by RT-PCR and
then cloned into EcoR I and Xho I sites of pcDNA3.1(+)
expression vector (Invitrogen). Substitution mutation,
deletion, and 2 or 3 CREB binding sites connection
constructs were generated by a PCR-based site-directed
mutagenesis kit (Takara), using corresponding plasmid
as the template. For eight-base substitutions, we
introduced the GCGCGCGC into the substitution sites.
Luciferase assay
In promoter assay, promoter reporter plasmid DNA was
transiently transfected into Hep3B and HL-7702 cells
using Lipofectamine 2000 (Invitrogen). pRL-TK
(Promega) was co-transfected as an internal control for
transfection eﬃciency. In miRNA sensor reporter assay,
recombinant psiCHECK plasmids (including both ﬁreﬂy
and Renilla luciferase reporter genes, with the former gene
as an internal control) containing possible miRNA target
sites were co-trasnsfected with miR-372 mimics with or
without miR-372 inhibitor as described earlier. After
further cultivation for 24h, the transfected cells were har-
vested, lysed, centrifuged and the pellet subjected to
luciferase assay. Luciferase activity was measured as
chemiluminescence in a luminometer (PerkinElmer Life
Sciences, Boston, MA, USA) using the Dual-Luciferase
5368 Nucleic Acids Research, 2010,Vol.38, No. 16reporter assay system (Promega) according to the manu-
facturer’s protocol. All transfections were performed in
triplicate, and the results were expressed as the
means±SD of three independent experiments.
Electrophoretic mobility shift assays
Electrophoretic mobility shift assay (EMSAs) were per-
formed using the gel shift kit (Promega). Nuclear extract
proteins (5.0mg) were incubated in 10ml of reaction con-
taining 4% glycerol, 1mM MgCl2, 0.5mM dithiothreitol,
0.5mM EDTA, 50mM NaCl, 10mM Tris–HCl, pH 7.5
and 2.0mg poly(dI–dC) with or without 30-fold excess of
unlabeled DNA competitors on ice for 10min followed by
the addition of the radio labeled probe. For supershift
assays, antibody against CERB or phospho-CREB was
added to the reaction mixture 10min before the addition
of the probe. All DNA–protein complexes were resolved
by electrophoresis on 5% native polyacrylamide.
Western blot analysis
Cells were harvested and lysed in 0.5ml of lysis buﬀer
(10mM Tris–HCl, pH 7.6, 5mM EDTA, 50mM NaCl,
30mM sodium pyrophosphate, 50mM NaF, 0.1mM
Na3VO4, 1% Triton X-100, 1mM phenylmethylsulfonyl
ﬂuoride and protease inhibitor mixture tablet (Roche
Applied Science, Indianapolis, IN, USA). Lysates were
clariﬁed by centrifugation at 15000g for 10min. Protein
(30mg) was processed for SDS–PAGE, which was per-
formed on 12% gels. The proteins were electrophoretically
transferred to Immobilon P (Bio-rad, Hercules, CA,
USA). The blots were blocked with 5% non-fat milk in
Tris–buﬀered saline (TBS, pH 7.4) for 1h and then
incubated with antibodies in 5% non-fat milk in TBS.
They were then washed with TBS and incubated with sec-
ondary antibodies conjugated with horseradish peroxidase
in 5% non-fat milk in TBS. After washing with TBS, the
bound antibodies were visualized by enhanced chemilu-
minescence (Pierce, Rockford, IL, USA) and recorded
on X-ray ﬁlms.
Statistical analysis
Statistical evaluations were conducted using the t-test.
P<0.05 were considered to be statistically signiﬁcant.
RESULTS
HULC is up-regulated in HCC and liver cancer cell lines
at transcription level
To validate early observation from previous report that
HULC was up-regulated in HCC (14), expression of
HULC in clinical specimens was assessed by quantitative
real-time PCR. In a collection of 14 pairs of randomly
chosen samples, HULC expression was up-regulated in
all tumor tissues compared to the corresponding
adjacent non-tumor liver specimens (Figure 1A). An
analysis of HULC expression in 10 diﬀerent liver cell
lines showed it to be up-regulated in liver cancer cell
lines (Huh-1, Huh-4, Hep3B, HepG2, Huh-7, SNU-449
and SNU-475) compared to that of normal liver cell
lines (QSG-7701, Chang liver and HL-7702). The degree
of HULC expression level was highest in Hep3B cells,
whereas almost undetectable in HL-7702 cells
(Figure 1B). Thus, Hep3B and HL-7702 cell lines were
selected as a research pair represents liver cancer and
normal cells in the following studies. To determine
whether up-regulation of HULC in liver cancer was
mainly at transcription level, a-amanitin, a RNA polymer-
ase II inhibitor (20), was applied. Treatment of Hep3B
and HL-7702 cells with a-amanitin in culture at a concen-
tration of 50mg/ml for 24h resulted in the inhibition
of HULC expression (Figure 1C), suggesting the
up-regulation of HULC expression is dependent of
transcription.
Open chromatin structure around the transcription
start site
The transcription start site (TSS) of the Hulc gene was
identiﬁed by 50 RACE analysis and predicted to be
 146bp from our gene-speciﬁc nested primer
(Figure 2A, left panel). Sequencing of PCR products
indicated that the ﬁrst base was C (Figure 2A, right
panel), which is 60bp downstream of the ﬁrst base
provided by the National Center for Biotechnology
Information (Gene ID: 728655). It is generally accepted
that the local chromatin structure aﬀects gene transcrip-
tion (21). We performed CHART-PCR assays, which
evaluates the accessibility of genomic DNA to nuclease
by comparing the quantity of intact DNA from a
nuclease-treated sample to that of an untreated sample
and is expressed inversely proportional to the protection
level (17), in an attempt to reveal diﬀerences of regions of
open chromatin around the Hulc gene promoter between
liver cancer and normal cell lines, in order to provide cues
in the search for the regulation sites at the promoter level.
Nuclei were isolated and subjected to digestion with
DNase I and restriction enzymes and the genomic frag-
ments between  10 028 and+9756bp (relative to the TSS)
were analyzed. In addition to the regions around TSS
(R2–R7, Figure 2B), another two representative regions
were also included: R1 region is a distal region upstream
the TSS and R8 region is a distal region downstream of
the Hulc gene. Thus, we were able to evaluate the nuclease
accessibility of the Hulc gene from 50 distal region to the 30
distal region. As shown in Figure 2C, the regions spanning
the proximal promoter (R4–R7) were more sensitive to
DNase I digestion, particularly, R7 (from  90 to +77)
exhibited the lowest protection level of  8% in Hep3B
cells, whereas  30% in HL-7702 cells. In comparison,
higher levels of protection against DNase I digestion
were seen at the R1 and the R8 region, furthermore, the
protection levels of R1 and R8 were not aﬀected as much
as those of R6 and R7 when using increasing concentra-
tions of DNase I (1, 3 and 7U) in both Hep3B and
HL-7702 cells. Thus, DNase I accessibility is limited to
the proximal promoter region (especially to the R7
region), and the degree of accessibility of cancer cells is
much greater than that of normal cells. To conﬁrm the
results performed by DNase I, a restriction enzyme acces-
sibility assay was employed. Nuclei isolated from Hep3B
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panel of restriction enzymes with recognition sites at dif-
ferent locations within the corresponding regions (Figure
2D, left panel). As shown in Figure 2D, in both cells, re-
striction sites of Hae III/R1 and Alu I/R8 were resistant to
nuclease digestion, indicating their coverage by nucleo-
somes. In contrast, stronger cleavage with lower protec-
tion was detected for Alu I/R6, and Sac I/R7 (Sac I was
stronger) in Hep3B cells than those of HL-7702 cells, sug-
gesting that these sites were in two linker regions, with
greater accessibility to restriction enzymes in a cancer de-
pendent manner.
Histone modiﬁcation around the promoter
Next, we evaluated whether HULC expression is
enhanced by epigenetic changes to the promoter by
ChIP assays. Acetylation has long been known to be
associated with actively transcribed genes and open chro-
matin conﬁgurations (22,23). Antibodies speciﬁc to
diacetylated H3 (K9 and K14) and tetra-acetylated H4
(K5, K8, K12 and K16) were used in ChIP analysis to
determine the pattern of histone modiﬁcation in a cancer
speciﬁc manner. In HL-7702 cells, both H3 and H4 were
acetylated at all the testing areas, with the highest level in
the R7 region. In cancer cells, histone acetylation was sig-
niﬁcantly increased in R7 region (Figure 2E and F). As for
histone methylation, trimethyl-H3K4 [an euchromatic
marker (24)] was scored signiﬁcantly higher in R4–R7
regions in cancer cells. As for the heterochromatin
marker Dimethyl-H3K9, which serves as a signal for chro-
matin silencing by recruiting the HP1 protein (heterochro-
matin protein 1) and is mutually exclusive with H3-K9
acetylation (25), it was scored lower in R6 and R7
regions in cancer cells (Figure 2G and H). Taken
together, these results indicate that transcription activa-
tion of HULC is correlated with an increase in the
local recruitment of euchromatic markers and a decrease
in that of the heterochromatic markers in the transcrip-
tional activation of Hulc gene expression in liver cancer
cells.
CREB-binding site contributes to the activation
of the promoter
The existence of a highest nuclease sensitive site (R7
region) strongly indicates the binding of transcription
factors as transcriptional regulators, prompting us to
examine the potential role of the cis elements at this
region. To examine the transcriptional activity of the se-
quences at the 50 end of the Hulc gene, various fragments of
the proximal sequence were cloned upstream of the ﬁreﬂy
luciferase reporter gene. A 50 deletion series with a ﬁxed 30
end at the+72 position (relative to the TSS) were generated
through PCR ampliﬁcation from genomic DNA of Hep3B
or HL-7702 cells. The constructs were transfected into
Hep3B and HL-7702 cells, respectively. All the constructs
(containing  132/ 48 fragment) tested were capable of
inducing a signiﬁcant increase in luciferase activity
compared with that of a promoter-less vector
(pGL3-Basic) (Figure 3A). This observation suggests that
the most proximal 84nt of the Hulc gene is capable of
initiating transcription. The promoter reporter containing
the shortest DNA fragment encompassing  132/ 48
region is named Luc-HCP hereafter. Surprisingly, no sig-
niﬁcant diﬀerence of activity in Hep3B compare with
HL-7702 cells was detected in any of the constructs. We
then performed a search for possible transcription
factor-binding sites using online software programs
MatInspector (www.genomatix.de/online_help/help_
matinspector/matinspector_help.html) and TFSEARCH
(www.cbrc.jp/research/db/TFSEARCH.html) revealed a
Lyf-1 and a CREB binding site within this region (Figure
3B). To conﬁrm the roles of these two sites in transcription
activity of the Hulc gene, deletion of either of these two
sites was tested for promoter function in the cell lines. The
results showed that when the CREB binding site is deleted,
promoter activities were reduced to background levels
(Figure 3C). However, no promoter activity change was
found when the Lyf-1 binding site is deleted. To further
test the possible CREB binding, we have generated a series
of 8bp mutations between  132 and  48nt within
Luc-HCP ( 132/+72) construct through a PCR-based
Figure 1. Up-regulation of HULC in HCC and liver cancer cell lines.
(A) Change in HULC expression between adjacent normal and HCC
tissues was quantiﬁed by real-time PCR. (B) HULC expression levels in
diﬀerent liver cell lines by semi-qRT-PCR. b-actin was treated as
internal control. (C) Hep3B and HL-7702 cells were stimulated with
a-amanitin (50mg/ml) for 24h. All results are means±SD of three
independent experiments. The asterisk indicates statistical signiﬁcance
at the P<0.01 level using t-test.
5370 Nucleic Acids Research, 2010,Vol.38, No. 16Figure 2. Analysis of chromatin accessibility around the Hulc promoter. (A)5 0RACE PCR products suggest the putative TSS is  146bp upstream
of the HULC reverse 50RACE primer (left panel). Mapping the TSS of Hulc in HCC (right panel). (B) Schematic representation of the DNA regions
around Hulc promoter, which can be ampliﬁed by corresponding primer sets. (C) DNase I accessibility of Hulc gene in Hep3B and HL-7702 cells.
Nuclei from two cell lines were harvested and treated with three units (left panel) or increasing amount (1–7 units, right panel) of DNase I for 5min
at room temperature. Then the genomic DNA was puriﬁed and quantitated relative to DNA from undigested nuclei using the primers described in
(B) by quantitative PCR and listed as percent protected. (D) Restriction enzymes accessibility of Hulc gene in Hep3B and HL-7702 cells. Nuclei was
treated with 25–150 units of restriction enzymes for 30min at 37 C. Then the genomic DNA was puriﬁed and quantitated relative to DNA from
undigested nuclei using the primers described in (B) by quantitative PCR and listed as percent protected. Chromatin from Hep3B and HL-7702 cells
were harvested and precipitated with anti-diacetyl-H3 (E), anti-tetra-acetyl-H4 (F), anti-tri-methyl-H3-K4 (G) and anti-dimethyl-H3-K9 (H)
antibodies. After DNA recovery, the precipitates were evaluated by real-time PCR for the level of enrichment over negative control antibody
using primer sets described in (B). All results are the means±SD of three independent experiments. The asterisk indicates statistical signiﬁcance
using t-test, *P<0.05; **P<0.01.
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mutation in M6, M7 and M13 (M13 overlaps M6 and
M7), which disrupts the CREB binding site reduced
promoter activity by >86%. No signiﬁcant changes in
promoter activity had been observed in other mutant con-
structs (Figure 3D). Moreover, additional one (2 ) or two
(3 ) possible CREB-binding sites increased promoter
activity of Luc-HCP (1 CREB), however, no signiﬁcant
increasing eﬀects were found between 2  CREB and 3 
CREB constructs, which may due to steric eﬀects (Figure
3E). These results demonstrate that the CREB binding site
is necessary for transcriptional initiation.
Figure 3. CREB-binding site contributes to the activation of the promoter. (A) Hep3B and HL-7702 cells were transiently co-transfected with
reporter plasmids containing truncated versions of the promoter region of the Hulc gene, as indicated, and pRL-TK. Luc-HCP is deﬁned as the
reporter containing the shortest promoter region (from  132 to+72), which core elements located in. (B) Transcription factor binding sites present in
the core promoter region (from  132 to  48) were predicated by web software TFSEARCH and MatInspector, as indicated by dashed lines.
(C) Cells were transiently transfected with wild-type Luc-HCP as well as Luc-HCP which Lyf-1 or CREB binding site was deleted. Lyf-1-binding site
is indicated by circle, whereas CREB-binding site is indicated by rectangle; deleted Lyf-1 and CREB sites are shown as black cycle and rectangle,
respectively. (D) Scanning mutational analysis of the fragment from  132 to 48. As shown on the upper panel, a series of 8-bp substitutions were
made within the fragment from  132 to 48 of the reporter construct Luc-HCP (from  132 to +72). M6, M7 and M13 overlap the possible
CREB-binding site. (E) Wild-type Luc-HCP and Luc-HCP containing additional one (2 ) or two (3 ) possible CREB-binding sites were
co-transfected with pRL-TK into Hep3B and HL-7702 cells. Fireﬂy luciferase activity was normalized to Renilla luciferase activity, and the
relative luciferase activities are presented as fold increase over the promoter-less pGL3 basic vector. Horizontal column lengths represent the
means±SD of three independent experiments.
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cancer
To test DNA–protein interactions in the promoter region,
we performed EMSA using the DNA sequence from  73
to  46 bearing the CREB binding site. Strong DNA–
protein complex was detected in both Hep3B and
HL-7702 cells (Figure 4A, lanes 1 and 4). To determine
whether the putative CREB binding site is involved in the
formation of these complexes, a 30-fold excess of un-
labeled oligonucleotide corresponding to  73 to  46 se-
quences was used to compete with the complexes. As
shown in lanes 2 and 5, the competitor competed away
the complexes possibly by sequestering the available tran-
scription factors present in the nuclear extract. These data
Figure 4. HULC expression is regulated by phospho-CREB through PKA pathway in liver cancer cells. (A) Upon interaction with the nuclear
extract of Hep3B (left panel) and HL-7702 (right panel), wild probe generated speciﬁc band (lanes 1 and 4) which was self-competed by 30-fold
excess of unlabeled probe (lanes 2 and 5). No competition was observed when using the same amounts of mutant probe (lanes 3 and 6).
(B) Interaction with anti-CREB antibody resulted in a super shift band formation in both two cell lines (lanes 2 and 4). (C) Interaction with
anti-phospho-CREB antibody resulted in a super shift band formation (lane 2) in Hep3B, but not detected in HL-7702 cell line (lane 4). (D) ChIP
analysis was performed to qualitative conﬁrm the interaction of CREB and CBP with the Hulc promoter in vivo in Hep3B (upper panel) and
HL-7702 (lower panel) cells using primer sets R1, R5, R7 and R8 described in Figure 2B. PCR products from the ChIP assay were run on an agarose
gel. As the negative controls, the protein–DNA complexes were incubated without antibodies or with non-speciﬁc control IgG. The input DNA
represents one-ﬁfth of the starting material. (E) Pre-incubation with H89 was performed 1day before transiently co-transfected Luc-HCP and
internal control pRL-TK plasmids into Hep3B and HL-7702 cells and further incubation for 1day in the continued presence of indicated
amount of H89. Fireﬂy luciferase activity was normalized to Renilla luciferase activity. Results are shown as relative percentage to those of cells
untreated H89. (F) Total RNA was extracted for measurement of HULC mRNA expression level after treatment by indicated amount of H89 by
real-time PCR. *P <0.05; **P <0.01 versus the corresponding untreated cells (E and F). (G) Endogenous CREB mRNA was quantiﬁed by real-time
PCR and normalized to b-actin RNA in Hep3B and HL-7702 cells (left panel). The whole lysates of Hep3B and HL-7702 cells were examined by
immunoblotting with antibodies against CREB, p-CREB and b-actin (right panel).
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binding capacity. In contrast, the unlabeled mutated
oligonucleotide bearing the disrupted CREB binding site
was unable to compete for protein binding capacity (lanes
3 and 6). To test if CREB is involved in the formation of
the protein–DNA complexes detected in the EMSA, we
performed supershift assays by using the anti-CREB
antibody. As illustrated in Figure 4B lane 2 and 4, a
super shift band was formed by antibody in nuclear
extracts from Hep3B and HL-7702 cells. These results
suggest that CREB can speciﬁcally interact with the
wild-type  73 to  46 sequence probe in both Hep3B
and HL-7702 cells. It is well known that phosphorylated
CREB binds to promoter region, allowing it to switch
certain genes on or oﬀ (26,27). Thus, we next perform
super shift assay again using anti-p-CREB antibody to
conform whether phospho-CREB binds to the Hulc
promoter in liver cancer cells. As expected, super shift
band was formed only in Hep3B cells, no super shift
band was detected in HL-7702 cells (Figure 4C, lanes 2
and 4). These results suggest that phospho-CREB forms
DNA–protein complexes in liver cancer cells in vitro.
We then performed ChIP assays to examine whether
CREB and its co-activator, CBP (CREB binding
protein) interact with the Hulc promoter in vivo.A s
shown in Figure 4D, anti-CREB antibody speciﬁcally
enriched the R7 region in both two cell lines, which con-
taining the CREB binding site. However, DNA fragments
immunoprecipated by anti-CBP antibody led to ampliﬁ-
cation of a single band using R7 primer sets only in
Hep3B cells. Collectively, cancer induced CREB phos-
phorylation may greatly enhance the increase in HULC
expression.
PKA pathway up-regulates HULC expression
In previous studies (28–30), it was determined that the
PKA pathway was responsible for immediate stimulation
of CREB. The importance of the PKA pathway was
examined by pretreatment of Hep3B and HL-7702 cells
with H89, an inhibitor of PKA (31). Pre-incubation of
indicated amount of H89 for 1day and then transfected
with Luc-HCP and further incubation for another 1day in
the continued presence of H89 blocked promoter activities
in a dose-dependent manner (Figure 4E) through reducing
phosphorylation of CREB (data not shown), and greatly
inhibited the HULC expression (Figure 4F) in Hep3B
cells. In contrary, no signiﬁcant changes were detected
both in promoter activity and HULC expression in
HL-7702 cells (Figure 4E and F). To examine whether
high HULC expression in liver cancer cells correlates
with CREB expression, we examined Hep3B cells and
HL-7702 cells for their expression patterns of CREB by
real-time PCR and western blotting. Surprisingly, the
CREB expression level in Hep3B cells was similar with
that of HL-7702 cells at transcription level (Figure 4G,
left panel), but was lower than that of the latter one at
translation level (Figure 4G, right panel). However,
phospho-CREB level was greatly enhanced in Hep3B
cells compared with that of HL-7702 cells (Figure 4G,
right panel). In addition, we sequenced cDNA of CREB,
and found no changes from Hep3B and HL-7702 cells
(data not shown), thus exclude possible sequences alter-
ation caused HULC up-regulation. Taken together,
phospho-CREB may involve in the up-regulation of
the HULC expression through activation of PKA
pathway.
Phospho-CREB recruits P300 and Brg I to the Hulc
promoter in liver cancer cells
Knockdown studies were performed to further test the
role of CREB in regulating Hulc promoter activation.
To address this, we inhibited CREB expression using
siRNA. Hep3B and HL-7702 cells were transfected with
CREB targeted siRNA and a scrambled siRNA as
control. The siRNA reduced the CREB mRNAs levels
remarkably (reduction by 83 and 84% for Hep3B and
HL-7702 cells, respectively) and resulted in inhibition of
both promoter activation and expression levels of HULC
(Figure 5A and B). Moreover, it was more obvious in
Hep3B cells than that of HL-7702 cells. ChIP assays
were next performed to monitor changes of histone acetyl-
ation. Histone deacetylation was observed after siRNA
induction (Figure 5C and D). Consistent with the
changes of HULC transcription (Figure 5A and B),
RNA Polymerase II (pol II) was observed at high level
under basal conditions, and decreased after knockdown
of CREB (Figure 5E). It has been previously reported
that transcription factors recruit the HAT P300 enzyme
binds core promoter regions, and that its binding correl-
ates with the presence of highly acetylated histones (21).
So, we performed a Re-ChIP assay in order to conﬁrm
whether phospho-CREB and P300 are co-recruited onto
the proximal promoter. In Re-ChIP analysis, we
immunoprecipitated the phospho-CREB or P300-
containing complexes with antibodies against P300 or
phospho-CREB, respectively, and only those DNA se-
quences that are simultaneously bound by both proteins
would be ampliﬁed in the subsequent PCR. Our results
showed that P300 and phospho-CREB were co-recruited
on the same DNA fragments (R7 region) (Figure 5F,
upper panel), suggesting that the two factors co-occupy
common target loci in Hep3B cells. We then performed
knockdown experiments to verify whether reduction of
CREB might dissociate the P300 enzyme away from
Hulc promoter sequences. The ChIP results showed that
P300 is present in the R7 region in untreated cells, a
decrease was observed after siRNA induction in Hep3B
cells (Figure 5G). Besides, we found that Brg1, the core
component of the SWI–SNF remodeling complex, which
can change the accessibility of nucleosome-packaged
DNA (21), co-occupied with phospho-CREB in the
same R7 region of the Hulc promoter (Figure 5F, upper
panel), whereas, no signiﬁcant bands were detected in
HL-7702 cells (Figure 5F, lower panel). These results
strongly support a direct role of phospho-CREB in P300
and Brg I recruitment to the Hulc promoter, leading to the
activation of epigenetic markers and chromatin remodel-
ing at the same location in liver cancer cells.
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Most recently, a report indicated that long ncRNA from
Arabidopsis thaliana contains motif with sequence comple-
mentary to miRNA, and coin the term ‘target mimicry’ to
deﬁne this mechanism of inhibition of miRNA activity
(32). To examine whether HULC has a similar mechanism
in liver cancer, prediction of miRNA target sites was
performed by the online software MicroInspector
(bioinfo.uni-plovdiv.bg/microinspector). As shown in
Supplementary Figure S1, HULC RNA contains many
elements complementary to various miRNA seed
regions. To obtain a ﬁrst insight into a possible role of
HULC in deregulation of miRNAs, the eﬀect of
siRNA-mediated knockdown of HULC expression was
Figure 5. Reduction of CREB results in changes of chromatin accessibility and histone acetylation. (A) RNAi for CREB reduced Hulc promoter
activity in Hep3B and HL-7702 cells. CREB or negative control siRNAs were co-transfected with Luc-HCP into cells. Luciferase assays were
performed 24h after transfection. Fireﬂy luciferase activity was normalized to Renilla luciferase activity. (B) Endogenous HULC mRNA was
quantiﬁed by real-time PCR and normalized to b-actin RNA. Chromatin from Hep3B and HL-7702 cells treated with control or CREB speciﬁc
siRNA was harvested and precipitated with anti-diacetyl-H3 (C), anti-tetra-acetyl-H4 (D) and anti-pol II (E) antibodies. After DNA recovery, the
precipitates were evaluated by real-time PCR for the level of enrichment over negative control antibody. (F) ChIP and re-ChIP experiments
performed with anti-phosph-CREB, anti-P300 and anti-Brg I antibodies on Hep3B and HL-7702 cells. (G) Chromatin from Hep3B cells treated
with control or CREB speciﬁc siRNA was harvested and precipitated with anti-P300 antibody. All the results (A–E and G) are the means of three
independent experiments±SD. Results of cells transfected siRNA against CREB are normalized to those of cells treated by negative control siRNA.
The asterisk indicates statistical signiﬁcance at the P<0.05 level using t-test.
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for HULC siRNA (data not shown). The expression
proﬁling of seven randomly chosen miRNAs were
measured in siRNA treated Hep3B cells by real-time
PCR. Surprisingly, the expression levels of almost all the
miRNAs were slightly down-regulated with exception of
miR-613 ( 1-fold increase, Supplementary Figure S1) and
miR-372 (over 3-fold increase, Figure 6A) in siRNA
treated cells compared with those of cells treated with
negative control siRNA, suggesting HULC does not
aﬀect miRNAs expression proﬁling in most cases. It may
due to low expression level of HULC that miR-372 ex-
pression level had no signiﬁcant change after siRNA treat-
ment in HL-7702 cells (Figure 6A). To verify HULC can
genuinely aﬀect miRNAs activities, sensors were con-
structed (Figure 6B and Supplementary Figure S1) as
described in ﬁgure legends. Reduction of Renilla luciferase
activities suggests induction of miRNAs activities. As
expected, the Renilla lucifease activities of all the chosen
miRNAs sensors greatly decreased (lowest in miR-372)
when cells treated with siRNA against HULC compared
with those of negative control (Figure 6B and
Supplementary Figure S1). These results indicated that
HULC may act as endogenous sponge ‘antagomirs’ as
described previously (33,34). To validate the observation
that HULC can reduce miR-372 expression in HCC, ex-
pression of miR-372 in clinical specimens was assessed by
real-time PCR. In a collection of 14 pairs of randomly
chosen samples, which were used for detection of HULC
expression levels described earlier, miR-372 was
down-regulated in all tumor tissues compared to the cor-
responding adjacent non-tumor liver tissues (Figure 6C).
In addition, expression levels of miR-372 signiﬁcantly
declined in liver cancer cell line, Hep3B compared to
normal live cell line, HL-7702 (Figure 6D), which is con-
sistent with the results in clinical samples (Figure 6C).
Taken together, HULC reduces not only expression, but
also activity of miR-372 in HCC.
Interaction between HULC and miR-372
As described above, H89 can reduce HULC expression.
As shown in Figure 7A, H89 induced expression of
miR-372 in a dose-dependent manner in Hep3B cells,
while no signiﬁcant change was detected in HL-7702
cells, suggesting reduction of miR-372 is associated with
expression of HULC. To further validate the inhibitory
Figure 6. HULC inhibits miR-372 expression and activity. (A) Expression proﬁling of miR-372 48h after HULC siRNA treatment in Hep3B and
HL-7702 cells. (B) Construction of miR-372 sensor (upper panel). Genomic sequences ( 200bp) ﬂanking pre-miRNAs were reverse inserted into the
psiCHECK vector, placing the 30UTR with the miRNA binding sites downstream of coding sequence of Renilla luciferase. Luciferase assays
indicated that enhanced miRNAs’ activities lead to decreasing levels of Renilla luciferase after treatment by HULC siRNA in Hep3B and
HL-7702 cells (lower panel). Renilla luciferase activities were normalized to ﬁreﬂy luciferase activities. *P <0.01, versus the cells treated with
negative control siRNA (A and B). (C) Change in miR-372 expression between adjacent normal and HCC tissues was quantiﬁed by real-time
PCR. *P <0.01, versus adjacent normal tissue. (D) Diﬀerences in miR-372 expression level between Hep3B and HL-7702 cell lines. *P<0.01, versus
Hep3B cells. All the results described above are means of three independent experiments±SD.
5376 Nucleic Acids Research, 2010,Vol.38, No. 16eﬀect of HULC on miR-372 activity, Hep3B and HL-7702
cells were incubated with indicated amount of H89 and
transfected with miR-372 sensor. The results indicated
that H89 induces miR-372 activity in liver cancer cells
(Figure 7B). Based on a recently study descried the
ability of miR-372 to overcome a p21-mediated cell cycle
arrest in the testicular germ cell tumor (35), we performed
cell cycle analysis. Results indicated that miR-372 regulate
cell cycle progression by inducing the S accumulation,
which is consistent with previous report. However, cells
incubated with H89 or siRNA against HULC enhanced
miR-372 induced eﬀects (data not shown). Bioinformatics
reveal HULC RNA contains one conserved target site of
miR-372 (Figure 7C, left panel). To verify the interaction
between HULC and miR-372, the HULC RNA was
cloned into psiCHECK vector (pSi-HULC), as described
in ﬁgure legends. The constructs were co-transfected
into Hep3B and HL-7702 cells with miR-372 mimics.
Luciferase assays revealed that over-expression of
miR-372 could signiﬁcantly reduce the Renilla luciferase
activities from the reporter pSi-HULC (Figure 7C, right
panel). To inhibit the function of miR-372, 20-O-methyle
antisense inhibitory oligoribonucleotides targeted toward
miR-372 was co-transfected, relative luciferase activities
were signiﬁcantly up-regulated compared to that of trans-
fected with miR-372 alone. To conﬁrm this putative target
site of miR-372, deletion assay was performed. Luciferase
assays indicated that over-expression of miR-372 had no
eﬀectiveness on deleted HULC RNA compared to the
wild-type. Furthermore, over-expression of HULC
(HULC wild-type) resulted in down-regulation of both
miR-372 expression and activities in a does-dependent
manner (Figure 7D and E). However, no signiﬁcant
change was detected between cells transfected with
pcDNA 3.1(+) empty vector and HULC without
miR-372 target site (HULC-Del-372). It may due to
higher expression level of miR-372 in HL-7702 cells,
which caused more obvious change compared with that
of in Hep3B cells when HULC was over-expressed. These
results revealed HULC may inhibit both expression and
activity of miR-372 by this putative binding site at
post-transcription level in both liver normal and cancer
cells.
Interaction between Prkacb and miR-372
As described earlier, phospho-CREB stimulates expres-
sion of HULC; furthermore, the level of phospho-CREB
is much higher in Hep3B cells than in HL-7702 cells
(Figure 4G). In the contrary, expression level of
miR-372 in Hep3B cells is much lower than that in
HL-7702 cells (Figure 6D). We hypothesized that reduc-
tion of miR-372 may decrease repression to its mRNA
targets, thus enhanced the phosphorylation of CREB
in liver cancer. So, we did a search for miR-372 target
mRNAs through online software: Tagetscan (www
.targetscan.org), MicroInspector and RNA22
(cbcsrv.watson.ibm.com/rna22_targets.html) revealed a
common target site in 30UTR of Prkacb (cAMP-
dependent protein kinase catalytic subunit beta) mRNA
(Figure 8A, left panel), the protein product of which can
translocate into nucleus and thus activate CREB (14,29).
The Prkacb 30UTR was then cloned into psiCHECK
vector (pSi-Prkacb). Luciferase assays indicated that
Prkacb mRNA is genuinely targeted by miR-372 (Figure
8A, right panel) according to the procedure described in
Figure 7C. However, Prkacb mRNA obtained no signiﬁ-
cant change after over-expression of miR-372 or miR-372
inhibitor for 1day revealed miR-372 without aﬀecting
Prkacb at the transcriptional level (data not shown). As
previous studies described that translation repression is
likely the predominant mechanism by which miRNAs
exert their function (11), we next examine PRKACB by
western blotting. As expected, after over-expression of
miR-372 for 1day, PRKACB was markedly decreased
compare to control resulted in reduction of
phospho-CREB (Figure 8B). Futhermore, the protein ex-
pression level is higher in Hep3B than that in HL-7702
cells (Figure 8C). Moreover, after over-expression of
HULC in HL-7702 cells, PRKACB was apparently
up-regulated resulted from down-regulation of both ex-
pression and activity of miR-372 (Figure 7D and E) at
translation level (Figure 8D). After transfected siRNA
against Prkacb, both promoter activity and expression of
HULC declined compared to that of control in Hep3B
cells, however, no signiﬁcant change was detected in
HL-7702 cells (Figure 8E and F). In conclusion, the
above data clearly demonstrate that reduction of
miR-372 mediated Prkacb inhibition results in facilitation
of phosporylation of CREB in liver cancer cells.
MiR-372 mediates dissociation of transcription factors
to the Hulc core promoter in vivo
In contrast with the results of the luciferase reporter
assays and western blotting that PRKACB was gradually
decreased resulted in phospho-CREB declining after
miR-372 induction, by which lead to reduction of
promoter activity from Luc-HCP (Figure 9A and B), the
ChIP results showed that 0.5h after miR-372 induction,
binding of CREB protein began to decrease with the
bottom level reached at 4h (Figure 9C), followed by
declining of CBP protein began at 1h with the bottom
level at 24h (Figure 9D). Consistent with the kinetics of
HULC transcription (Figure 9E), an increase in nuclease
protection level was observed with Sac I digestion using
R7 primer sets as early as 1h and gradually increased
during the whole detection period (Figure 9F).
Collectively, local dissociation of CBP by CREB protein
under miR-372-induced conditions reduces the level of
chromatin opening of the core promoter, and thus de-
creases expression of HULC.
DISCUSSION
In our study, we ﬁrst identiﬁed the mechanism by which
CREB up-regulates the expression of lncRNA, HULC in
a cancer-speciﬁc manner and found the speciﬁc interaction
of CREB with the Hulc promoter through its binding site
located between  67 and  53nt (Figures 3 and 4). We
show that in this core promoter (i) phospho-CREB
binding at its binding site through PKA pathway is
Nucleic Acids Research, 2010,Vol.38, No. 16 5377Figure 7. Interaction between HULC RNA and miR-372. (A) Relative fold change of miR-372 in the presence of indicated amount of H89 for 24h.
(B) Pre-incubation with H89 was performed 1day before transiently transfected miR-372 sensor into Hep3B and HL-7702 cells and further incu-
bation for 1day in the continued presence of indicated amount of H89. *P<0.05 and **P<0.01, versus the cells untreated with H89 (A and B). (C)
Sequence inspection by microInspector online software reveals HULC RNA contains a conserved element complementary to miR-372 (left panel).
psiCHECK vectors containing HULC RNA with (pSi-HULC, wild-type) or without (pSi-HULC, deletion) predicted miR-372 binding site were
co-transfected with miR-372 or both miR-372 and miR-372 inhibitor simultaneously (right panel). Luciferase assays were performed 24h
post-transfection. *P<0.05. (D) The indicated amount of HULC-pcDNA3.1(+) with or without miR-372 binding site and empty vectors were
transfected into Hep3B and HL-7702 cells grown on a six-well plate for 48h. Then the total RNA was extracted for detection of miR-372.
**P<0.01. (E) The miR-372 sensor reporter plasmid was co-transfected with pcDNA3.1(+) vector as described in (D) and then cells were harvested,
lysed, centrifuged and the pellet subjected to luciferase assay. *P<0.05 and **P<0.01, versus cells transfected with empty vectors. Renilla luciferase
activity was normalized to Fireﬂy luciferase activity (C and E). All results are shown as means of three independent experiments±SD.
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phospho-CREB binding may result in an open chromatin
conﬁguration associated with local histone. Therefore, the
present study delineates the fundamental elements of a
core promoter structure that will be helpful for future
studies on the diﬀerential regulation of Hulc expression
in liver.
CREB is a ubiquitous transcription factor that activates
the transcriptional activity of various promoters through
its binding site (36). A typical sequence of events is as
follows: the catalytic subunit of activated protein kinase
A, including PRKACB (the inactive holoenzyme of PKA
is a tetramer composed of two regulatory and two cata-
lytic subunits. cAMP causes the dissociation of the
inactive holoenzyme into a dimer of regulatory subunits
bound to four cAMP and two free monomeric catalytic
subunits.) translocates to the cell nucleus, where it
phosphorylated CREB (37). The activated CREB
protein binds to a CRE (cAMP response element)
region, and is then bound to by CBP, which coactivates
it, allowing it to switch certain genes on or oﬀ (38,39).
Additionally, CREB may create a core promoter
Figure 8. Interaction between Prkacb and miR-372. (A) Prkacb 30UTR contains a miR-372 target site, as shown in the left panel, and conﬁrmed by
Luciferase assays (right panel). pSi-Prkacb contains Prkacb 30UTR. Experimental procedure is similar with that described in Figure 7C.
(B) Immunoblotting assay indicated that over-expression of miR-372 (50nM) results in down-regulation of PRKACB, thus reduces phosphorylation
of CREB in Hep3B cells. (C) Diﬀerences in PRKACB expression level between Hep3B and HL-7702 cell lines were measured by immunoblotting
assay. (D) PRKACB expression level was detected by immunoblotting assay after transfection with pcDNA3.1(+) vector as indicated in HL-7702
cells. (E) Prkacb or negative control siRNAs were co-transfected with Luc-HCP into Hep3B and HL-7702 cells. Luciferase assays were performed
24h after transfection. Fireﬂy luciferase activities were normalized to Renilla luciferase activities. (F) Endogenous HULC mRNA was quantiﬁed by
real-time PCR and normalized to b-actin RNA. Results of RNAi are shown as fold change to the control. *P<0.01 versus corresponding control
cells. All results are shown as means of three independent experiments±SD.
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complex (40). In our study, using PKA inhibitor, H89
could reduce both promoter activity and expression of
HULC in liver cancer cells (Figure 4). Furthermore,
knockdown of CREB expression resulted in an inhibition
of the promoter activation as well as endogenous HULC
transcription level (Figure 5). Therefore, we show directly
that phospho-CREB is crucial for Hulc promoter activity
in liver cancer cells. The association of phospho-CREB
protein with its binding site contained in this region may
result in the recruitment of histone acetyltransferases
(such as P300 and CBP) to the promoter, leading to the
acetylation of the histone tail and maintaining the open
conﬁguration of the local chromatin. Furthermore, such
events occurring at the proximal promoter provide chro-
matin accessibility to polymerase II to initiate the tran-
scription of the Hulc gene (Figure 5).
SWI/SNF complex has the ability of mobilizing nucleo-
somes and remodeling chromatin (21,41). In comparison
to normal liver cells, the SWI/SNF complex was found to
be associated speciﬁcally with the proximal promoter
region in cancer cells (Figure 5). It is suﬃcient to yield a
Figure 9. Over-expression of miR-372 inhibits Hulc promoter activity. (A) Luciferase assays indicated that miR-372 could reduce promoter activity
of Luc-HCP in Hep3B cells compared to that of HL-7702 cells. Fireﬂy luciferase activity was normalized to Renilla luciferase activity, and the
relative luciferase activities are presented as fold increase over the promoter-less pGL3-basic vector. *P<0.01 versus control cells.
(B) Immunoblotting assays indicated that over-expression of miR-372 could gradually down-regulation of PRKACB, thus reduce phosphorylation
of CREB in Hep3B cells. Chromatin from Hep3B and HL-7702 cells was harvested 0, 0.5, 1, 2, 3, 4 and 24h and precipitated with anti-CREB (C)
and anti-CBP (D) antibodies. After DNA recovery, the precipitates were evaluated by real-time PCR for the level of enrichment over the negative
control antibody. (E) Down-regulation of HULC expression by miR-372 (50nM) treatment in Hep3B cells compared to that of HL-7702 cells for the
indicated periods of time after replacement of transfection medium containing 50nM miR-372 mimics with 5% FBS. (F) Nuclei were harvested 0,
0.5, 1, 2 and 24h from Hep3B and HL-7702 cells. Then digested with Sac I. Puriﬁed DNA was quantitated by real-time PCR and relative to DNA
from undigested nuclei using the primers compassing R7 region and listed as percent protected. *P<0.05, **P<0.01 versus cells harvested at 0h
(A and C–F). All the results are the means of three independent experiments±SD.
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releasing nucleosome from the CREB binding site. This
primes for an increase in the HULC transcription level by
facilitating of CREB enrichment, and it can further recruit
P300. The putative P300 and CREB complex may
up-regulate the H3 and H4 acetylation levels that are re-
sponsible for the initiation and maintenance of enhanced
local chromatin accessibility to the general transcription
apparatus, thus up-regulates the HULC expression level
(Figure 2).
In this study, when we tried to delineate the Hulc
promoter in liver cancer and normal cell lines, a conven-
tional method, luciferase reporter assay was used. After
transient transfection of the luciferase reporter containing
the proximal promoter, the reporter plasmids showed no
signiﬁcant increasing activity in cancer cell lines compare
with normal cell lines (Figure 3). We think that, unlike
stably transfected plasmids or episomal constructs, the
chromatin structure of transiently transfected plasmids is
usually incomplete or aberrant, and may vary with cell
type and the transfection method used. We postulate
that in our transient transfection experiment, the
proximal promoter region had not been packaged into a
chromatin-like structure, and may even have been in a
‘naked’ state, and as a result, CREB binding site and the
TSS may not have been occupied by nucleosomes, leading
to high accessibility to various nuclear factors. Hence,
cancer status cannot exert its regulatory role through re-
modeling the chromatin structure, and up-regulated
promoter activity was undetectable in our luciferase
reporter assay. Therefore, it is important that the
promoter activity is studied in its native chromatin
context.
RNA is not only a messenger operating between DNA
and protein. Although lncRNAs are among the least
well-understood of transcript species, they cannot all be
dismissed as merely transcriptional ‘noise’. At least for the
exception of HULC that: (i) its expression varies from
diﬀerent cell lines (Figure 1B); and, (ii), its expression
can be up-regulated in liver cancer (Figure 1A). As
previous studies described that lncRNA sequences
convey functions through binding to DNA or protein.
However, in this work, we provide additional evidence
of lncRNA as an inhibitor to short ncRNA, miRNAs in
liver cancer, in other contexts; HULC can also exert its
functions through interaction with other RNAs (Figure 7).
In our hands, depletion of HULC by speciﬁc siRNA
enhanced miRNAs activities not through up-regulating
miRNAs expression but instead reducing its ability of se-
questering miRNAs at most cases. Franco-Zorrilla et al.
(32) reported that a non-protein coding RNA, IPS1 from
A. thaliana contains a motif with sequence complementary
to the phosphate (Pi) starvation-induced miRNA,
miR-399, however, IPS1 RNA is not cleaved but instead
sequesters miR-399. Thus, IPS1 over-expression results in
increased accumulation of the miR-399 target PHO2
mRNA and, concomitantly, in reduced shoot Pi content.
Ebert et al. (34) developed competitive miRNA inhibitors,
termed ‘miRNA sponges’ containing multiple, tandem
binding sites to miRNAs of interest, by which can block
an entire miRNA seed family. By the information
collected above, we think HULC may act as an endogen-
ous ‘miRNA sponge’, which regulates miRNAs activities
in liver cancer cells. Apart from the above mentioned, not
only activities but also expression levels of miR-372 and
miR-613 can be aﬀected by HULC, indicates there exists
another pathway involved in HULC inhibitory to
miRNAs. Recently, a family of exoribonucleases
encoded by the small RNA degrading nuclease genes
degrade mature miRNAs were found in Arabidopsis (42).
Besides, miRNAs that are partially complementary to the
target can also speed up deadenylation, causing miRNAs
to be degraded sooner. Binding of miR-372 and miR-613
to their seed regions in HULC may stimulate such
nuclease or facilitate miRNA deadenylation results in
degrading of miRNAs (43). Further studies are required
to fully deﬁne such mechanism. Furthermore, we
demonstrated that through pairing with partially comple-
mentary sites in 30UTRs, miR-372 mediate post-
transcriptional silencing of PRKACB, which ﬁnally
aﬀects phosphorylation of CREB in liver cancer.
Upon miR-372 treatment, gradually reduction of
PRKACB through its miR-372 binding site in the
30UTR accompanied with dephosphorylation of CREB
(Figure 9). However, the PRKACB level was transiently
up-regulated followed by induced phosphorylation of
CREB 2h after induction, but still lower than the basal
level (Figure 9B), may due to compensation of the loss of
PRKACB. Because PRKACB plays an important role in
maintaining the normal function of cells (14), transient
up-regulating the level of PRKACB may get more
chances of survival. A decrease in CREB and CBP
binding to the promoter is apparent at 30min after
miR-372 treatment (Figure 9C and D), which makes the
chromatin from the proximal promoter region begin to
close after 1h of induction (Figure 9F). Such dissociation
is slowly, gradually decreasing during the entire detection
time—it is suﬃcient to yield a state of close conﬁguration
of the local chromatin through recruiting nucleosome to
the TSS. This primes for a gradual decrease in the HULC
transcription level by masking the CREB-binding sites,
and in turn further reduces CREB and CBP binding to
the promoter.
The regulatory circuitry described here provides
another example of how gene reprogramming during
tumorigenesis relies on ﬁne modulation of gene expres-
sion. It is also interesting to note that ﬁne tuning of
HULC expression is part of an autoregulatory loop in
which it’s inhibitory to expression and activity of
miR-372 allows the establishment of the lncRNA
up-regulated expression in liver cancer. CREB may be
the link for up-regulation of HULC (Figure 1A) and
down-regulation of miR-372 (Figure 6C) in HCC.
HULC inhibitory to miR-372 reduces miRNA mediated
translational repression of PRKACB, which can induce
phosphorylation of CREB, in turn, stimulates HULC ex-
pression (Figure 10). Notably, the relevant function of
HULC up-regulation would be not only increase of
PRKACB mediated functions, which appear quite
crucial, but also other putative substrates not yet tested,
possibly important for cell-lineage speciﬁcation. Besides, it
is also important to mention that the activation of CREB,
Nucleic Acids Research, 2010,Vol.38, No. 16 5381to a certain extent, may be the initial event of
up-regulating HULC expression, because HULC is
widely expressed, including liver cancer and normal cells
(Figure 1B), however, HULC does not exert its function
of inhibitory to miR-372 in normal cells as obvious as that
in cancer cells. Environments in cancer cells may diﬀerent
from that in normal cells. Stimuli involved in the PKA
pathway that can induce phosphorylation of CREB have
been excellently reviewed elsewhere (44). Once HULC is
up-regulated, miR-372 can be rapidly absorbed to the
putative binding site in HULC and then may be cleared,
by such event, enhances HULC expression and further
inhibition to miR-372. Collectively, we think reduction
of miR-372 is not only the result, but also a driving
factor for greater suppression of HULC to other
miRNAs, although more details need to be elucidated.
In conclusion, in this work we demonstrated that CREB
up-regulates the HULC expression level by interaction
with miR-372, which in turn initiates a cascade of molecu-
lar events to increase the chromatin accessibility for the
general transcription in liver cancer.
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Figure 10. Possible molecular mechanism underlying interaction between HULC and miR-372.
5382 Nucleic Acids Research, 2010,Vol.38, No. 16REFERENCES
1. Ponting,C.P., Oliver,P.L. and Reik,W. (2009) Evolution and
functions of long nonocoding RNAs. Cell, 136, 629–641.
2. Wang,J., Zhang,J., Zheng,H., Li,J., Liu,D., Li,H., Samudrala,R.,
Yu,J. and Wong,G.K. (2004) Mouse transcriptome: neutral
evolution of ‘non-coding’ complementary DNAs. Nature, 431,
757–761.
3. Lau,N.C., Lim,L.P., Weinstein,E.G. and Bartel,D.P. (2001) An
abundant class of tiny RNAs with probable regulatory roles in
Caenorhabditis elegans. Science, 294, 858–862.
4. Lagos-Quintana,M., Rauhut,R., Lendeckel,W. and Tuschl,T.
(2001) Identiﬁcation of novel genes coding for small expressed
RNAs. Science, 294, 853–858.
5. Lee,R.C. and Ambros,V. (2001) An extensive class of small
RNAs in Caenorhabditis elegans. Science, 294, 862–864.
6. Mattick,J.S. (2001) Non-coding RNAs: the architects of
eukaryotic complexity. EMBO Rep., 2, 986–991.
7. Costa,F.F. (2005) Non-codig RNAs: new players in eukaryotic
biology. Gene, 357, 83–94.
8. Lu,J., Getz,G., Miska,E.A., Alvarez-Saavedra,E., Lamb,J.,
Peck,D., Sweet-Cordero,A., Ebert,B.L., Mak,R.H., Ferrando,A.A.
et al. (2005) MicroRNA expression proﬁles classify human
cancers. Nature, 435, 834–838.
9. Bentwich,I., Avniel,A., Karov,Y., Aharonov,R., Gilad,S.,
Barad,O., Barzilai,A., Einat,P., Einav,U., Meiri,E. et al. (2005)
Identiﬁcation of hundreds of conserved and nonconserved human
microRNAs. Nat. Genet., 37, 766–770.
10. Jopling,C.L., Yi,M., Lancaster,A.M., Lemon,S.M. and Sarnow,P.
(2005) Modulation of hepatitis C virus RNA abundance by a
liver-speciﬁc MicroRNA. Science, 309, 1577–1581.
11. Sun,F., Wang,J., Pan,Q., Yu,Y., Zhang,Y., Wan,Y., Wang,J.,
Li,X. and Hong,A. (2009) Characterization of function and
regulation of miR-24-1 and miR-31. Biochem. Biophys. Res.
Commun., 380, 660–665.
12. Bosch,F.X., Ribes,J., Cle ´ ries,R. and Dı´az,M. (2005) Epidemiology
of hepatocellular carcinoma. Clin. Liver Dis., 9, 191–211.
13. Panzitt,K., Tschernatsch,M.M., Guelly,C., Moustafa,T.,
Stradner,M., Strohmaier,H.M., Buck,C.R., Denk,H.,
Schroeder,R., Trauner,M. et al. (2007) Characterization of
HULC, a novel gene with striking up-regulation in hepatocellular
carcinoma, as noncoding RNA. Gastroenterology, 132, 330–342.
14. Matouk,I.J., Abbasi,I., Hochberg,A., Galun,E., Dweik,H. and
Akkawi,M. (2009) Highly upregulated in liver cancer noncoding
RNA is overexpressed in hepatic colorectal metastasis. Eur. J.
Gastroenterol. Hepatol., 21, 688–692.
15. Wu,K.J., Mattioli,M., Morse,H.C. and Dalla-Favera,R. (2002)
c-MYC activates protein kinase A (PKA) by direct transcriptional
activation of the PKA catalytic subunit beta (PKA-C beta) gene.
Oncogene, 21, 7872–7882.
16. Rao,S., Procko,E. and Shannon,M.F. (2001) Chromatin
remodeling, measured by a novel real-time polymerase chain
reaction assay, across the proximal promoter region of the IL-2
Gene. J. Immunol., 167, 4494–4503.
17. Sun,F., Xie,Q., Ma,J., Yang,S., Chen,Q. and Hong,A. (2009)
Nuclear factor Y is required for basal activation and chromatin
accessibility of ﬁbroblast growth factor receptor 2 promoter in
osteoblast-like cells. J. Biol. Chem., 284, 3136–3147.
18. Xue,X., Sun,J., Zhang,Q., Wang,Z., Huang,Y. and Pan,W. (2008)
Identiﬁcation and characterization of novel microRNAs from
Schistosoma japonicum. PLoS ONE, 3, e4034.
19. Hurteau,G.J., Carlson,J.A., Spivack,S.D. and Brock,G.J. (2007)
Overexpression of the microRNA hsa-miR-200c leads to reduced
expression of transcription factor 8 and increased expression of
E-cadherin. Cancer Res., 67, 7972–7976.
20. Lee,Y., Kim,M., Han,J., Yeom,K.H., Lee,S., Baek,S.H. and
Kim,K.N. (2004) MicroRNA genes are transcribed by RNA
polymerase II. EMBO J., 23, 4051–4060.
21. Sun,F., Chen,Q., Yang,S., Pan,Q., Ma,J., Wan,Y., Chang,C.H.
and Hong,A. (2009) Remodeling of chromatin structure within
the promoter is important for bmp-2-induced fgfr3 expression.
Nucleic Acids Res., 37, 3897–3911.
22. Spencer,V.A. and Davie,J.R. (1999) Role of covalent modiﬁcations
of histones in regulating gene expression. Gene, 240, 1–12.
23. Tse,C., Sera,T., Wolﬀe,A.P. and Hansen,J.C. (1998) Disruption of
higher-order folding by core histone acetylation dramatically
enhances transcription of nucleosomal arrays by RNA polymerase
III. Mol. Cell Biol., 18, 4629–4638.
24. Shilatifard,A. (2008) Molecular implementation and physiological
roles for histone H3 lysine 4 (H3K4) methylation. Curr. Opin.
Cell Biol., 20, 341–348.
25. Vakoc,C., Mandat,S., Olenchock,B. and Blobel,G. (2005) Histone
H3 lysine 9 methylation and HP1g are associated with
transcription elongation through mammalian chromatin.
Mol. Cell, 19, 381–391.
26. Du,K. and Montminy,M. (1998) CREB is a regulatory target for
the protein kinase Akt/PKB. J. Biol. Chem., 273, 32377–32379.
27. Chrivia,J.C., Kwok,R.P., Lamb,N., Hagiwara,M.,
Montminy,M.R. and Goodman,R.H. (1993) Phosphorylated
CREB binds speciﬁcally to the nuclear protein CBP. Nature, 365,
855–859.
28. Gonzalez,G.A. and Montminy,M.R. (1989) Cyclic AMP
stimulates somatostatin gene transcription by phosphorylation of
CREB at Serine 133. Cell, 59, 675–680.
29. Chen,A.E., Ginty,D.D. and Fan,C.M. (2005) Protein kinase A
signalling via CREB controls myogenesis induced by Wnt
proteins. Nature, 433, 317–322.
30. Li,Y., Yin,W., Wang,X., Zhu,W., Huang,Y. and Yan,G. (2007)
Cholera toxin induces malignant glioma cell diﬀerentiation via the
PKA/CREB pathway. Proc. Natl Acad. Sci. USA, 104,
13438–13443.
31. Leemhuis,J., Boutillier,S., Schmidt,G. and Meyer,D.K. (2002) The
protein kinase A inhibitor H89 acts on cell morphology by
inhibiting Rho kinase. J. Pharmacol. Exp. Ther., 300, 1000–1007.
32. Franco-Zorrilla,J.M., Valli,A., Todesco,M., Mateos,I., Puga,M.I.,
Rubio-Somoza,I., Leyva,A., Weigel,D., Garcı´a,J.A. and Paz-
Ares,J. (2007) Target mimicry provides a new mechanism for
regulation of microRNA activity. Nat. Genet., 39, 1033–1037.
33. Krutzfeldt,J., Rajewsky,N., Braich,R., Rajeev,K.G., Tuschl,T.,
Manoharan,M. and Stoﬀel,M. (2005) Silencing of microRNAs
in vivo with ‘antagomirs’. Nature, 438, 685–689.
34. Ebert,M.S., Neilson,J.R. and Sharp,P.A. (2007) MicroRNA
sponges: competitive inhibitors of small RNAs in mammalian
cells. Nat. Methods, 4, 721–726.
35. Voorhoeve,P., le Sage,C., Schrier,M., Gillis,A., Stoop,H.,
Nagel,R., Liu,Y., van Duijse,J., Drost,J. and Griekspoor,A.
(2006) A Genetic screen implicates miRNA-372 and miRNA-373
as oncogenes in testicular germ cell tumors. Cell, 124, 1169–1181.
36. Mayr,B. and Montminy,M. (2001) Transcriptional regulation by
the phosphorylation-dependent factor CREB. Nat. Rev. Mol. Cell
Biol., 2, 599–609.
37. Delghandi,M.P., Johannessen,M. and Moens,U. (2005) The
cAMP signalling pathway activates CREB through PKA, p38 and
MSK1 in NIH 3T3 cells. Cell Signal., 17, 1343–1351.
38. Du,K. and Montminy,M. (1998) CREB is a regulatory target for
the protein kinase Akt/PKB. J. Biol. Chem., 273, 32377–32379.
39. Chrivia,J.C., Kwok,R.P., Lamb,N., Hagiwara,M.,
Montminy,M.R. and Goodman,R.H. (1993) Phosphorylated
CREB binds speciﬁcally to the nuclear protein CBP. Nature, 365,
855–859.
40. Narayan,S., Beard,W.A. and Wilson,S.H. (1995) DNA
damage-induced transcriptional activation of a human DNA
polymerase beta chimeric promoter: recruitment of
preinitiation complex in vitro by ATF/CREB. Biochemistry, 34,
73–80.
41. Wang,X., Sansam,C.G., Thom,C.S., Metzger,D., Evans,J.A.,
Nguyen,P.T. and Roberts,C.W. (2009) Oncogenesis caused by loss
of the SNF5 tumor suppressor is dependent on activity of BRG1,
the ATPase of the SWI/SNF chromatin remodeling complex.
Cancer Res., 69, 8094–8101.
42. Ramachandran,V. and Chen,X. (2008) Degradation of
microRNAs by a family of exoribonucleases in Arabidopsis.
Science, 5895, 1490–1492.
43. Lu,S., Sun,Y.H. and Chiang,V.L. (2009) Adenylation of plant
miRNAs. Nucleic Acids Res., 37, 1878–1885.
44. Johannessen,M., Delghandi,M.P. and Moens,U. (2004) What
turns CREB on? Cell Signal., 16, 1211–1227.
Nucleic Acids Research, 2010,Vol.38, No. 16 5383